Discover unique lipid nanoparticles with high delivery efficiency; Develop therapeutics targeting multiple organ systems; Collaborate on external programs for AI and ML-developed nanoparticles; Enhance drug delivery systems for serious diseases; Utilize AI for novel therapeutic development
Raised $86 million in Series A financing; Appointed Mark Herbert as Chief Business Officer; Partnered with Evopoint Biosciences for licensing; Joined Roche Accelerator for drug development support